Susan Mesco | Pacira Pharmaceuticals, Inc. |
David M. Stack | Pacira Pharmaceuticals, Inc. |
Richard E. Scranton | Pacira Pharmaceuticals, Inc. |
Charles A. Reinhart III | Pacira Pharmaceuticals, Inc. |
Ashley Ryu | RBC Capital Markets LLC |
Douglas D. Tsao | Barclays Capital, Inc. |
David A. Amsellem | Piper Jaffray & Co. |
David Michael Steinberg | Jefferies LLC |
Corey George Davis | Seaport Global Securities LLC |
Serge Belanger | Needham & Co. LLC |
Ami Fadia | Leerink Partners LLC |
Good day, ladies and gentlemen, and welcome to the Q2 2018 Pacira Pharmaceuticals Earnings Conference Call. At this time, all participants are in a listen-only mode.
Following management's prepared remarks, we will have a question-and-answer session, and instructions will be given at that time. And as a reminder, today's conference is being recorded for replay purposes. I would now like to introduce your host for today's conference, Susan Mesco, Head of Investor Relations.